Clinical Trial

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Study acronym: MajesTEC-4
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2022-02-07; most recent amendment 2026-06-03.
Status change: Not Yet Recruiting → Recruiting 2022-09-26
Trial Details
NCT Number NCT05243797
Lead Sponsor European Myeloma Network B.V.
Collaborators: Janssen Pharmaceutica
Conditions Multiple Myeloma
Enrollment 1,594 participants
Start Date 2022-09-08
Primary Completion 2028-04 (estimated)
Study Completion 2032-04 (estimated)
Updated on ClinicalTrials.gov 2026-06-04